Neurobiology of Aging
Volume 30, Issue 9 , Pages 1333-1349 , September 2009

Epistasis in sporadic Alzheimer's disease

  • Onofre Combarros

      Affiliations

    • Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Marqués de Valdecilla University Hospital (University of Cantabria), 39008 Santander, Spain
    • ,
  • Mario Cortina-Borja

      Affiliations

    • Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK
    • ,
  • A. David Smith

      Affiliations

    • Oxford Project To Investigate Memory and Ageing (OPTIMA), Oxford Centre for Gene Function, University Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford OX1 3QB, UK
    • ,
  • Donald J. Lehmann

      Affiliations

    • Oxford Project To Investigate Memory and Ageing (OPTIMA), Oxford Centre for Gene Function, University Department of Physiology, Anatomy and Genetics, South Parks Road, Oxford OX1 3QB, UK
    • Corresponding Author InformationCorresponding author.

Received 16 July 2007 ,Revised 30 November 2007 ,Accepted 30 November 2007.

References 

  1. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, et al. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum. Genet. 2001;109:646–652
  2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 2000;21:383–421
  3. American Psychiatric Association . DSM-III-R. Diagnostic and Statistical manual of mental disorders. 3rd rev ed.. Washington, DC: American Psychiatric Association; 1987;
  4. American Psychiatric Association . DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed.. Washington: American Psychiatric Association; 1994;
  5. Arias-Vásquez A, Isaacs A, Aulchenko YS, Hofman A, Oostra BA, Breteler M, et al. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics. 2007;8:189–193
  6. Bagli M, Papassotiropoulos A, Jessen F, Rao ML, Maier W, Heun R. Gene–gene interaction between interleukin-6 and α2-macroglobulin influences the risk for Alzheimer's Disease. Ann. Neurol. 2000;47:138–139
  7. Bagnoli S, Cellini E, Tedde A, Nacmias B, Piacentini S, Bessi V, et al. Association of IL10 promoter polymorphism in Italian Alzheimer's disease. Neurosci. Lett. 2007;418:262–265
  8. Bernardini S, Bellincampi L, Ballerini S, Federici G, Iori R, Trequattrini A, et al. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E ɛ4 allele. Clin. Chem. 2005;51:944–951
  9. Berrington de González A, Cox DR. Additive and multiplicative models for the joint effect of two risk factors. Biostatistics. 2005;6:1–9
  10. Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci. Lett. 2000;288:21–24
  11. Bian L, Yang JD, Guo TW, Sun Y, Duan SW, Chen WY, et al. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology. 2004;63:241–245
  12. Bian J-T, Zhang J-W, Zhang Z-X, Shao H-L. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese. Neurosci. Lett. 2005;387:11–16
  13. Blázquez L, De Juan D, Ruiz-Martínez J, Emparanza JI, Sáenz A, Otaegui D, et al. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiol. Aging. 2007;28:1941–1943
  14. Bosco P, Caraci F, Copani A, Spada RS, Sortino MA, Salluzzo R, et al. The CDC2 I-G-T haplotype associated with the APOE ɛ4 allele increases the risk of sporadic Alzheimer's disease in Sicily. Neurosci. Lett. 2007;419:195–198
  15. Brune S, Kölsch H, Ptok U, Majores M, Schulz A, Schlosser R, et al. Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer's disease. J. Neural. Transm. 2003;110:1041–1050
  16. Bullido MJ, Guallar-Castillón P, Artiga MJ, Ramos MC, Sastre I, Aldudo J, et al. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neurosci. Lett. 2000;289:213–216
  17. Bullido MJ, Ramos MC, Ruiz-Gómez A, Tutor AS, Sastre I, Frank A, et al. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiol. Aging. 2004;25:853–859
  18. Cai L, Tang G, Chen L, Zhang B, Jiang S, Ren D. Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients. Neuroreport. 2005;16:1023–1026
  19. Capurso C, Solfrizzi V, D’Introno A, Colacicco AM, Capurso SA, Capurso A, et al. Interleukin 6–174G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp. Gerontol. 2004;39:1567–1573
  20. Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 2007;50:12–38
  21. Cash AD, Perry G, Ogawa O, Raina AK, Zhu X, Smith MA. Is Alzheimer's disease a mitochondrial disorder?. Neuroscientist. 2002;8:489–496
  22. Cathcart HM, Hsuang R, Lanham IS, Corder EH, Poduslo SE. Cystatin C as a risk factor for Alzheimer disease. Neurology. 2005;64:755–757
  23. Cellini E, Bagnoli S, Tedde A, Nacmias B, Piacentini S, Sorbi S. Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2005;19:246–247
  24. Chapuis J, Tian J, Shi J, Bensemain F, Cottel D, Lendon C, et al. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol. Aging. 2006;27:1212–1215
  25. Chen D, Zhang J-W, Zhang Z-X, Wu Y-N, Qu Q-M. Association of α2-macroglobulin polymorphisms and Alzheimer disease in mainland Han Chinese. J. Neurol. Sci. 2004;217:13–15
  26. Cheng D, Huang R, Lanham IS, Cathcart HM, Howard MEH, Poduslo CSE. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J. Med. Genet. 2005;42:129–131
  27. Chiappelli M, Borroni B, Archetti S, Calabrese E, Corsi MM, Franceschi M, et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res. 2006;9:485–493
  28. Cho YM, Ritchie MD, Moore JH, Park JY, Lee K-U, Shin HD, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia. 2004;47:549–554
  29. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 2000;71 (Suppl.):621S–629S
  30. Clarimon J, Bertranpetit J, Calafell F, Boada M, Tarraga L, Comas D. Association study between Alzheimer's disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol. 2003;250:956–961
  31. Combarros O, Infante J, Llorca J, Peña N, Fernández-Viadero C, Berciano J. The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis. Neurosci. Lett. 2002;326:33–36
  32. Combarros O, García-Román M, Fontalba A, Fernández-Luna JL, Llorca J, Infante J, et al. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement Geriatr. Cogn. Disord. 2003;15:151–154
  33. Combarros O, Infante J, Llorca J, Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2004;18:257–260
  34. Combarros O, Infante J, Llorca J, Peña N, Fernández-Viadero C, Berciano J. Interaction between interleukin-6 and intercellular adhesion molecule-1 genes and Alzheimer's disease risk. J. Neurol. 2005;252:485–487
  35. Combarros O, Riancho JA, Infante J, Sañudo C, Llorca J, Zarrabeitia MT, et al. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 2005;20:153–157
  36. Combarros O, Llorca J, Sánchez-Juan P, Mateo I, Infante J, Rodríguez E, et al. Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer's disease risk. J. Neurol. 2007;254:115–117
  37. Combarros O, Riancho JA, Arozamena J, Mateo I, Llorca J, Infante J, et al. Interaction between estrogen receptor-α and butyrylcholinesterase genes modulates Alzheimer's disease risk. J. Neurol. 2007;254:1290–1292
  38. Compton D, Wavrant DeVrièze F, Petersen RC, Tangalos E, Li L, Hardy J. Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers. Neurosci. Lett. 2002;331:60–62
  39. Crawford FC, Freeman MJ, Schinka JA, Morris MD, Abdullah LI, Richards D, et al. Association between Alzheimer's disease and a functional polymorphism in the myeloperoxidase gene. Exp. Neurol. 2001;167:456–459
  40. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron. 2003;38:9–12
  41. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann. Neurol. 2005;57:373–380
  42. Dermaut B, Theuns J, Sleegers K, Hasegawa H, Van den Broeck M, Vennekens K, et al. The gene encoding nicastrin, a major γ-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am. J. Hum. Genet. 2002;70:1568–1574
  43. Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci. Lett. 2002;328:9–12
  44. Di Natale M, Perri M, Kawarai T, Maletta R, Tomaino C, Sato C, et al. Absence of association between Alzheimer's disease and the regulatory region polymorphism of the PS2 gene in an Italian population. Neurosci. Lett. 2003;343:210–212
  45. Dickson MR, Perry RT, Wiener H, Go RCP. Association studies of transforming growth factor-β1 and Alzheimer's disease. Am. J. Med. Genet. B (Neuropsychiatr. Genet.). 2005;139B:38–41
  46. D’Introno A, Solfrizzi V, Colacicco AM, Capurso C, Torres F, Capurso SA, et al. Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease. J. Gerontol. A. 2005;60:280–284
  47. Edland SD, Wavrant-De Vrièse F, Compton D, Smith GE, Ivnik R, Boeve BF, et al. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci. Lett. 2003;345:21–24
  48. Eerligh P, Koeleman BPC, Dudbridge F, Bruining GJBO, Giphart RMJ. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immunity. 2004;5:36–40
  49. Ezquerra M, Blesa R, Tolosa E, Ballesta F, Oliva R. α-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. Neurosci. Lett. 1998;240:107–109
  50. Fallin D, Reading S, Schinka J, Hoyne J, Scibelli P, Gold M, et al. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am. J. Med. Genet. (Neuropsych. Genet.). 1997;74:192–194
  51. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis; the APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–1356
  52. Farrer LA, Abraham CR, Haines JL, Rogaeva EA, Song Y, McGraw WT, et al. Association between bleomycin hydrolase and Alzheimer's disease in Caucasians. Ann. Neurol. 1998;44:808–811
  53. Feinstein DL, Heneka MT, Gavrilyuk V, Russo CD, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 2002;41:357–365
  54. Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, et al. Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum. Genet. 2000;107:391–396
  55. Flex A, Gaetani E, Papaleo P, Straface G, Proia AS, Pecorini G, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke. 2004;35:2270–2275
  56. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 1999;10:245–257
  57. Gambaro G, Anglani F, D’Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet. 2000;355:308–311
  58. Golanska E, Hulas-Bigoszewska K, Wojcik I, Rieske P, Styczynska M, Peplonska B, et al. CYP46: a risk factor for Alzheimer's disease or a coincidence?. Neurosci. Lett. 2005;383:105–108
  59. Gold G, Blouin JL, Herrmann FR, Michon A, Mulligan R, Duriaux Saïl G, et al. Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE ɛ4 carriers. Am. J. Med. Genet. B. 2003;119:44–47
  60. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 2004;90:724–733
  61. Grubber JM, Saunders AM, Crane-Gatherum AR, Scott WK, Martin ER, Haynes CS, et al. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci. Lett. 1999;269:115–119
  62. Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 2000;275:16638–16642
  63. Haines JL, Pritchard ML, Saunders AM, Schildkraut JM, Growdon JH, Gaskell PC, et al. No genetic effect of α1-antichymotrypsin in Alzheimer disease. Genomics. 1996;33:53–56
  64. Harold D, Jehu L, Turic D, Hollingworth P, Moore P, Summerhayes P, et al. Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. Am. J. Med. Genet. Part B. 2007;144:448–452
  65. Hatanaka Y, Kamino K, Fukuo K, Mitsuda N, Nishiwaki-Ueda Y, Sato N, et al. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin. Genet. 2000;58:319–323
  66. Healy DG. Case-control studies in the genomic era: a clinician's guide. Lancet Neurol. 2006;5:701–707
  67. Helbecque N, Cottel D, Hermant X, Amouyel P. Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiol. Aging. 2007;28:1215–1220
  68. Hernandez-Charro B, Moreno S, Valiente A, Manubens JM, Villar MD, Ramos-Arroyo MA. ACT/AA polymorphism could duplicate the APOE*ɛ4-associated Alzheimer's disease risk. Med. Clin. (Barc.). 2004;123:251–254
  69. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 2001;29:571–581
  70. Howlett DR, Simmons DL, Dingwall C, Christie G. In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci. 2000;23:565–570
  71. Huang R, Huang J, Cathcart H, Smith S, Poduslo SE. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J. Med. Genet. 2007;44:e66
  72. Hyman BT, Strickland D, Rebeck GW. Role of the low-density lipoprotein receptor-related protein in β-amyloid metabolism and Alzheimer's disease. Arch. Neurol. 2000;57:646–650
  73. Iivonen S, Helisalmi S, Mannermaa A, Alafuzoff I, Lehtovirta M, Soininen H, et al. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology. Neurosci. Lett. 2003;352:146–150
  74. Infante J, Sanz C, Fernández-Luna JL, Llorca J, Berciano J, Combarros O. Gene–gene interaction between interleukin-1A and interleukin-8 increases Alzheimer's disease risk. J. Neurol. 2004;251:482–483
  75. Infante J, Sanz C, Fernández-Luna JL, Llorca J, Berciano J, Combarros O. Gene–gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology. 2004;63:1135–1136
  76. Infante J, Llorca J, Mateo I, Rodríguez-Rodríguez E, Sánchez-Quintana C, Sánchez-Juan P, et al. Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 2007;23:215–218
  77. In’t Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001;345:1515–1521
  78. Ioannidis JPA, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat. Genet. 2001;29:306–309
  79. Ioannidis JPA, Trikalinos TA, Nitzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003;361:567–571
  80. Janciauskiene S, Rubin H, Lukacs CM, Wright HT. Alzheimer's peptide Aβ1–42 binds to two β-sheets of α1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 1998;273:28360–28364
  81. Jia L, Ye J, Haiyan LV, Wang W, Zhou C, Zhang X, et al. Genetic association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the North Chinese population. Brain Res. 2007;1141:10–14
  82. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627–1631
  83. Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, et al. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum. Genet. 2004;114:581–587
  84. Kajiya A, Kaji H, Isobe T, Takeda A. Precessing of amyloid β-peptides by neutral cysteine protease bleomycin hydrolase. Protein Pept. Lett. 2006;13:119–123
  85. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nat. Genet. 1995;10:486–488
  86. Kamino K, Nagasaka K, Imagawa M, Yamamoto H, Yoneda H, Ueki A, et al. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem. Biophys. Res. Commun. 2000;273:192–196
  87. Keller JN, Hanni KB, Markesbery WR. Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J. Neurochem. 1999;72:2601–2609
  88. Kim J-M, Stewart R, Shin I-S, Jung J-S, Yoon J-S. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer's disease in an older Korean population. Neurobiol. Aging. 2004;25:295–301
  89. Kim K-W, Suh Y-J, Park W-Y, Jhoo J-H, Lee D-Y, Youn J-C, et al. Choline acetyltransferase G+4 A polymorphism confers a risk for Alzheimer's disease in concert with apolipoprotein E ɛ4. Neurosci. Lett. 2004;366:182–186
  90. Kirschling CM, Kölsch H, Frahnert C, Rao ML, Maier W, Heun R. Polymorphism in the BACE gene influences the risk for Alzheimer's disease. Neuroreport. 2003;14:1243–1246
  91. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, et al. Role of oxidized LDL in atherosclerosis. Ann. N.Y. Acad. Sci. 2001;947:199–205
  92. Koivisto AM, Helisalmi S, Pihlajamäki J, Moilanen L, Kuusisto J, Laakso M, et al. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J. Neurogenet. 2005;19:155–161
  93. Koster MN, Dermaut B, Cruts M, Houwing-Duistermaat JJ, Roks G, Tol J, et al. The α2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology. 2000;55:678–684
  94. Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease: the Japanese Genetic Study Consortium for Alzheimer's Disease. Hum. Mol. Genet. 2006;15:2170–2182
  95. Lambert JC, Luedecking-Zimmer E, Merrot S, Hayes A, Thaker U, Desai P, et al. Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. J. Med. Genet. 2003;40:424–430
  96. Lambert J-C, Mann D, Harris J, Araria-Goumidi L, Chartier-Harlin M-C, Cottel D, et al. Association study of notch 4 polymorphisms with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 2004;75:377–381
  97. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 1997;6:1933–1936
  98. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience. 2001;108:541–554
  99. Leininger-Muller B, Hoy A, Herbeth B, Pfister M, Serot J-M, Stavljenic-Rukavina M, et al. Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neurosci. Lett. 2003;349:95–98
  100. Li X-Q, Chen D, Zhang Z-X, Qu Q-M, Zhang J-W. Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population. Dement. Geriatr. Cogn. Disord. 2004;18:115–119
  101. Licastro F, Chiappelli M, Grimaldi LME, Morgan K, Kalsheker N, Calabrese E, et al. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol. Aging. 2005;26:449–453
  102. Lim U, Peng K, Shane B, Stover PJ, Litonjua AA, Weiss ST, et al. Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men. J. Nutr. 2005;135:1989–1994
  103. Luedecking-Zimmer E, DeKosky ST, Chen Q, Barmada MM, Kamboh MI. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum. Genet. 2002;111:443–451
  104. Ma DQ, Whitehead PL, Menold MM, Martin ER, Ashley-Koch AE, Mei H, et al. Identification of significant association and gene–gene interaction of GABA receptor subunit genes in autism. Am. J. Hum. Genet. 2005;77:377–388
  105. Mariani E, Seripa D, Ingegni T, Nocentini G, Mangialasche F, Ercolani S, et al. Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. J. Neurol. Sci. 2006;247:187–191
  106. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002;31:429–434
  107. Martin ER, Bronson PG, Li Y-J, Wall N, Chung R-H, Schmechel DE, et al. Interaction between the α-T catenin gene (VR22) and APOE in Alzheimer's disease. J. Med. Genet. 2005;42:787–792
  108. Mateo I, Infante J, Rodríguez E, Berciano J, Combarros O. Interaction between dopamine β-hydroxylase and interleukin genes increases Alzheimer's disease risk. J. Neurol. Neurosurg. Psychiatry. 2006;77:278–279
  109. Matsubara-Tsutsui M, Yamagata H, Morishima A, Nakura J, Mitsuda N, Kamino K, et al. The -4,752C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. Intern. Med. 2002;41:823–828
  110. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631–639
  111. McCusker SM, Curran MD, Dynan KB, McCullagh CD, Urquhart DD, Middleton D, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet. 2001;357:436–439
  112. McIlroy SP, Vahidassr MD, Savage DA, Lloyd F, Patterson CC, Lawson JT, et al. Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. Int. J. Geriat. Psychiatry. 2000;15:260–266
  113. McIlroy SP, Dynan KB, Vahidassr DJ, Lawson JT, Patterson CC, Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. Am. J. Med. Genet. (Neuropsych. Genet.). 2001;105:502–506
  114. McIntire WE, MacCleery G, Garrison JC. The G protein β subunit is a determinant in the coupling of Gs to the β1-adrenergic and A2a adenosine receptors. J. Biol. Chem. 2001;276:15801–15809
  115. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984;34:939–944
  116. Mesulam M-M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 1994;36:722–727
  117. Minster RL, DeKosky ST, Kamboh MI. No association of dynamin binding protein (DNMBP) gene SNPs and Alzheimer's disease. Neurobiol. Aging. 2007;(Epub ahead of print)
  118. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  119. Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat. Genet. 1998;18:211–212
  120. Moore JH, Williams SM. New strategies for identifying gene–gene interactions in hypertension. Ann. Med. 2002;34:88–95
  121. Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. BioEssays. 2005;27:637–646
  122. Morgan K, Morgan L, Carpenter K, Lowe J, Lam L, Cave S, et al. Microsatellite polymorphism of the α1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum. Genet. 1997;99:27–31
  123. Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, et al. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β. Neurobiol. Dis. 2005;19:66–76
  124. Muramatsu T, Matsushita S, Arai H, Sasaki H, Higuchi S. α1-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease. J. Neural. Transm. 1996;103:1205–1210
  125. Musani SK, Shriner D, Liu N, Feng R, Coffey CS, Yi N, et al. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum. Hered. 2007;63:67–84
  126. Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM-F, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement. Geriatr. Cogn. Disord. 1998;9:219–226
  127. Nicoll JAR, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et al. Association of Interleukin-1 gene polymorphisms with Alzheimer's disease. 2000;47:365–368
  128. Nowotny P, Kwon JM, Chakraverty S, Nowotny V, Morris JC, Goate AM. Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport. 2001;12:1799–1802
  129. Ntais C, Polycarpou A, Ioannidis JPA. Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review. Am. J. Epidemiol. 2004;159:527–536
  130. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001;60:759–767
  131. Ott J. Association of genetic loci: replication or not, that is the question. Neurology. 2004;63:955–958
  132. Panza F, Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Capurso A, et al. Shifts in angiotensin 1 converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk. J. Neurol. Neurosurg. Psychiatry. 2003;74:1159–1161
  133. Papassotiropoulos A, Bagli M, Jessen F, Frahnert C, Rao ML, Maier W, et al. Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease. Mol. Psychiatry. 2000;5:213–215
  134. Perry G, Nunomura A, Hirai K, Zhu X, Pérez M, Avila J, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Rad. Biol. Med. 2002;33:1475–1479
  135. Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, et al. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ɛ4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Aβ(1–42) level. Neurobiol. Dis. 2007;25:609–613
  136. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003;9:94–101
  137. Poli M, Gatta LB, Archetti S, Padovani A, Albertini A, Finazzi D. Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease. Neurosci. Lett. 2003;350:77–80
  138. Poli M, Gatta LB, Lovati C, Mariani C, Galimberti D, Scarpini E, et al. Interaction between the APOE ɛ4 allele and the APH-1b c+651T>G SNP in Alzheimer's disease. Neurobiol. Aging. 2007;(Epub ahead of print)
  139. Porrello E, Monti MC, Sinforiani E, Cairati M, Guaita A, Montomoli C, et al. Estrogen receptor α and APOEɛ4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur. J. Neurol. 2006;13:639–644
  140. Praticò D, Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimer's Dis. 2004;6:171–175
  141. Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J, et al. An association study of the N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur. J. Hum. Genet. 2005;13:807–814
  142. Quan W, Yasuda M, Hashimoto M, Yamamoto Y, Ishii K, Kazui H, et al. Polymorphism of the regulatory region of the presenilin-2 gene in sporadic Alzheimer's disease: a case-control study. J. Neurol. Sci. 2006;240:71–75
  143. Raina AK, Takeda A, Nunomura A, Perry G, Smith MA. Genetic evidence for oxidative stress in Alzheimer's disease. NeuroReport. 1999;10:1355–1357
  144. Raygani AV, Zahrai M, Soltanzadeh A, Doosti M, Javadi E, Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci. Lett. 2004;371:142–146
  145. Relton CL, Wilding CS, Pearce MS, Laffling AJ, Jonas PA, Lynch SA, et al. Gene–gene interaction in folate-related genes and risk of neural tube defects in a UK population. J. Med. Genet. 2004;41:256–260
  146. Remarque EJ, Bollen EL, Weverling-Rijnsburger AW, Laterveer JC, Blauw GJ, Westendorp RG. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol. 2001;36:171–176
  147. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, et al. MPO and APOEɛ4 polymorphisms interact to increase risk for AD in Finnish males. Neurology. 2000;55:1284–1290
  148. Riazanskaia N, Lukiw WJ, Grigorenko A, Korovaitseva G, Dvoryanchikov G, Moliaka Y, et al. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. Mol. Psychiatry. 2002;7:891–898
  149. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am. J. Hum. Genet. 2001;69:138–147
  150. Robson KJH, Lehmann DJ, Wimhurst VLC, Livesey KJ, Combrinck M, Merryweather-Clarke AT, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 2004;41:261–265
  151. Rodríguez E, Mateo I, Infante J, Llorca J, Berciano J, Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE ɛ4 allele. J. Neurol. 2006;253:181–185
  152. Rodríguez E, Mateo I, Llorca J, Sánchez-Quintana C, Infante J, Berciano J, et al. Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk. J. Neurol. 2006;253:801–803
  153. Rodríguez-Rodríguez E, Mateo I, Llorca J, Sánchez-Quintana C, Infante J, García-Gorostiaga I, et al. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am. J. Med. Genet. Part B. 2007;144:964–968
  154. Rogers J, Strohmeyer R, Kovelowski CJ, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. GLIA. 2002;40:260–269
  155. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, et al. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. Am. J. Med. Genet. Part B. 2004;125:87–91
  156. Sala Frigerio C, Piscopo P, Calabrese E, Crestini A, Malvezzi Campeggi L, Civita di Fava R, et al. PEN-2 gene mutation in a familial Alzheimer's disease case. J. Neurol. 2005;252:1033–1036
  157. Sheu K-FR, Brown AM, Haroutunian V, Kristal BS, Thaler H, Lesser M, et al. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population. Ann. Neurol. 1999;45:48–53
  158. Sheu K-FR, Brown AM, Kristal BS, Kalaria RN, Lilius L, Lannfelt L, et al. A DLST genotype associated with reduced risk for Alzheimer's disease. Neurology. 1999;52:1505–1507
  159. Shibata N, Kawarai T, Lee JH, Lee H-S, Shibata E, Sato C, et al. Association studies of cholesterol metabolism genes (CH25H ABCA1 and CH24H) in Alzheimer's disease. Neurosci. Lett. 2006;391:142–146
  160. Shobab LA, Hsiung G-YR , Feldman HH. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005;4:841–852
  161. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum. Mol. Genet. 1998;7:937–939
  162. Spell C, Kölsch H, Lütjohann D, Kerksiek A, Hentschel F, Damian M, et al. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele. Dement. Geriatr. Cogn. Disord. 2004;18:245–249
  163. Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications. J. Intern. Med. 2003;253:120–127
  164. Streit WJ, Conde JR, Harrison JK. Chemokines and Alzheimer's disease. Neurobiol. Aging. 2001;22:909–913
  165. Talbot C, Houlden H, Craddock N, Crook R, Hutton M, Lendon C, et al. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Neuroreport. 1996;7:534–536
  166. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron. 2004;43:605–608
  167. Terreni L, Fogliarino S, Quadri P, Ruggieri RMFP, Tettamanti M, Lucca U, et al. Tumor necrosis factor α polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population. Neurosci. Lett. 2003;344:135–137
  168. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet. 2004;20:640–647
  169. Tilley L, Morgan K, Grainger J, Marsters P, Morgan L, Lowe J, et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur. J. Hum. Genet. 1999;7:659–663
  170. Tsai C-T, Lai L-P, Lin J-L, Chiang F-T, Hwang J-J, Ritchie MD, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004;109:1640–1646
  171. Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am. J. Geriatr. Psychiatry. 2005;13:1062–1066
  172. van Oijen M, Arp PP, de Jong FJ, Hofman A, Koudstaal PJ, Uitterlinden AG, et al. Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia: the Rotterdam Study. Neurosci. Lett. 2006;402:113–117
  173. Wade MJ. Epistasis, complex traits, and mapping genes. Genetica. 2001;112/113:59–69
  174. Wang B, Zhang C, Zheng W, Lu Z, Zheng C, Yang Z, et al. Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. Neurosci. Lett. 2004;369:104–107
  175. Wiebusch H, Poirier J, Sévigny P, Schappert K. Further evidence for a synergistic association between APOEɛ4 and BCHE-K in confirmed Alzheimer's disease. Hum. Genet. 1999;104:158–163
  176. Williams SM, Addy JH, Phillips JAr , Dai M, Kpodonu J, Afful J, et al. Combinations of variations in multiple genes are associated with hypertension. Hypertension. 2000;36:2–6
  177. Williams SM, Ritchie MD, Phillips JAr, Dawson E, Prince M, Dzhura E, et al. Multilocus analysis of hypertension: a hierarchical approach. Hum. Hered. 2004;57:28–38
  178. Wollmer MA, Sleegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics. 2007;8:179–188
  179. Xiong M, Feghali-Bostwick CA, Arnett FC, Zhou X. A systems biology approach to genetic studies of complex diseases. FEBS Lett. 2005;579:5325–5332
  180. Yamada R, Tanaka T, Unoki M, Nagai T, Sawada T, Ohnishi Y, et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am. J. Hum. Genet. 2001;68:674–685
  181. Ye S, Dhillon S, Seear R, Dunleavey L, Day LB, Bannister W, et al. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart. 2003;89:1195–1199
  182. Yoshiiwa A, Kamino K, Yamamoto H, Kobayashi T, Imagawa M, Nonomura Y, et al. α1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E ɛ4 allele carriers. Ann. Neurol. 1997;42:115–117
  183. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry. 2005;62:217–224
  184. Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, La Russa A, et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch. Neurol. 2004;61:341–344

PII: S0197-4580(07)00463-0

doi: 10.1016/j.neurobiolaging.2007.11.027

Neurobiology of Aging
Volume 30, Issue 9 , Pages 1333-1349 , September 2009

Article Tools